Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005520 · ClinicalTrials.gov registry record
Genetic Epidemiology of Responses to Antihypertensives
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 1,200
- Enrollment target
NCT00005520: Completed study, sponsored by Mayo Clinic.
NCT00005520 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 1,200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005520 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 1,200 participants
- Enrollment target
Study Summary
To determine whether measured variation in genes coding for components of vasoconstriction and volume regulating systems predict interindividual differences in blood pressure response to therapy with a thiazide diuretic, hydrochlorothiazide, or an angiotensin II receptor blocker, candesartan, in hypertensive African-Americans (N=300 treated with each drug) and in hypertensive European Americans (N=300 treated with each drug).
Interventions
- DRUG Candesartan
- DRUG Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 1997-02 |
| Est. Completion | 2008-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005520
The ClinicalTrials.gov registry entry for NCT00005520 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Candesartan is the first listed.
NCT00005520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005520 about?
NCT00005520 is a clinical study titled "Genetic Epidemiology of Responses to Antihypertensives". To determine whether measured variation in genes coding for components of vasoconstriction and volume regulating systems predict interindividual differences in blood pressure response to therapy with a thiazide diuretic, hydrochlorothiazide, or an angiotensin II receptor blocker, candesartan, in hyp...
What is the current status of trial NCT00005520?
This trial is currently completed. The enrollment target is 1,200 participants. The study started on 1997-02. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00005520?
The interventions under investigation include: Candesartan (DRUG), Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00005520?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.